| __timestamp | Lantheus Holdings, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72429000 | 59644696 |
| Thursday, January 1, 2015 | 78634000 | 79541000 |
| Friday, January 1, 2016 | 75374000 | 98015000 |
| Sunday, January 1, 2017 | 92157000 | 103958000 |
| Monday, January 1, 2018 | 93326000 | 103654000 |
| Tuesday, January 1, 2019 | 103132000 | 128951000 |
| Wednesday, January 1, 2020 | 110171000 | 135799000 |
| Friday, January 1, 2021 | 218817000 | 149883000 |
| Saturday, January 1, 2022 | 233827000 | 220206000 |
| Sunday, January 1, 2023 | 267194000 | 265542000 |
Unleashing insights
In the dynamic world of pharmaceuticals, understanding spending patterns can offer a glimpse into a company's strategic priorities. Lantheus Holdings, Inc. and Travere Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Lantheus Holdings saw a remarkable increase in SG&A expenses, growing by approximately 270%. This surge reflects their aggressive expansion and investment in operational capabilities. In contrast, Travere Therapeutics experienced a more moderate increase of around 345% during the same period, indicating a steady yet strategic approach to scaling their operations.
By 2023, both companies reported SG&A expenses nearing parity, with Lantheus at $267 million and Travere at $266 million. This convergence highlights a competitive landscape where both companies are vying for market leadership through strategic spending.
AbbVie Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Lantheus Holdings, Inc.
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Opthea Limited
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Lantheus Holdings, Inc. vs ACADIA Pharmaceuticals Inc.
Lantheus Holdings, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Lantheus Holdings, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ligand Pharmaceuticals Incorporated vs Travere Therapeutics, Inc.